Rs429358

From SNPedia
Jump to: navigation, search

is asnp
is mentioned by
dbSNPrs429358
nextbiors429358
hapmaprs429358
1000 genomesrs429358
hgdprs429358
ensemblrs429358
gopubmedrs429358
scholarrs429358
googlers429358
pharmgkbrs429358
gwascentralrs429358
openSNPrs429358
23andMers429358
23andMe allrs429358
SNP Nexus

SNPshotrs429358
SNPdbers429358
MSV3drs429358
GeneAPOE
Chromosome19
Orientationplus
Position45411941
ReferenceGRCh37 37.1/131
Max Magnitude1.2
Geno Mag Summary
(C;C) 1.2 one of 2 snps relevant to classifying APOE genotype
(C;T) >3x increased risk for Alzheimer's; 1.4x increased risk for heart disease
(T;T) 0 common
? (C;C) (C;T) (T;T) 28

This SNP, located in the fourth exon of the ApoE gene, affects the amino acid at position 130 of the resulting protein. The more common rs429358 allele is (T). If the allele is (C) and the same chromosome also harbors the rs7412(C) allele, the combination is known as an ApoE4 allele. The ApoE4 allele has a strong influence on the risk of Alzheimer's disease. Both deCODEme and 23andMe (v3 chip) test for this SNP.

Many studies have estimated the level of risk, and it varies depending on age, sex, ethnicity, and other factors. One meta-analysis estimated the odds ratios for homozygous rs429358(C;C) individuals compared to the more common ApoE3/ApoE3 homozygotes to be 12x for late-onset Alzheimer's and 61x for early-onset disease. [PMID 10325447]

Meta-analyses have also supported the association between the ApoE4 allele and somewhat increased risk for heart disease, with an odds ratio of 1.42 (CI: 1.26 - 1.61).[PMID 15488874]

Note: Although ApoE status is technically defined by these two SNPs, rs429358 and rs7412, a SNP in the adjacent ApoC1 gene, rs4420638, is co-inherited with ApoE and thus often - though not completely - predictive of it.

OMIM107741
DescHYPERLIPOPROTEINEMIA, TYPE III, AUTOSOMAL DOMINANT
Variant0008
Relatedalso
OMIM107741
DescALZHEIMER DISEASE 2
Variant0016
Relatedalso
OMIM107741
DescHYPERLIPOPROTEINEMIA, TYPE III, ASSOCIATED WITH APOE4
Variant0022
Relatedalso
Neighborrs28931577
Distance39
Neighborrs28931578
Distance67


Venter snp
Source plos
Gene APOE
allele C
frequency
sift TOLERATED
HuRef 1103691153316
Disease Association The APOE*4 allele is associated with late onset Alzheimer disease 2 (AD2) (MIM:104310). The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.



OMIM601367
DescSTROKE, ISCHEMIC
Variant
Relatedalso

[PMID 19818961] Apolipoprotein E genotype is associated with serum C-reactive protein but not abdominal aortic aneurysm

PharmGKBPA165109610
NameAPOE: Cys112Arg (g.7903T>C, c.388T>C, p.Cys130Arg in dbSNP build 130)
AnnotationRisk or phenotype-associated allele: The ApoE E2 allele is a combination of rs429358 T (130Cys) and rs7412 T (176Cys). Phenotype: The Apo E2 allele contributes to increased risk of type III hyperlipoproteinemia, characterized by increased cholesterol and triglyceride levels, the presence of beta-VLDL (cholesterol-enriched remnants of intestinal chylomicrons and hepatic VLDL), xanthomas, and premature vascular disease, both coronary heart disease and peripheral artery disease. Study size: Three multiplex, multigenerational pedigrees, and case control study of 5 probands versus 94 controls. Study population/ethnicity: Germans. Significance metric(s): N/A. Type of association: CO; GN
GeneAPOE, APOC1
Featue
EvidencePubMed ID:199847
Drugs
DiseasesArteriosclerosis, Hyperlipoproteinemia Type III, Hyperlipoproteinemias, Vascular Diseases
Curation LevelCurated
GWAS snp
PMID [PMID 20100581]
Trait Brain imaging
Title Whole Genome Association Study of Brain-Wide Imaging Phenotypes for Identifying Quantitative Trait Loci in MCI and AD: A Study of the ADNI Cohort
Risk Allele
P-val NS
Odds Ratio None None


[PMID 20406466] Genetic variants associated with fasting blood lipids in the U.S. population: Third National Health and Nutrition Examination Survey

[PMID 20429872] Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study

[PMID 20822524] Isoform of APOE with retained intron 3; quantitation and identification of an associated single nucleotide polymorphism

[PMID 20946940] Association of variants within APOE; SORL1; RUNX1; BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome

PharmGKBPA162355841
NameAPOE: 3937T>C, p.Cys112Arg, (g.7903T>C, c.388T>C, p.Cys130Arg in dbSNP build 130)
AnnotationRisk or phenotype-associated allele: ApoE E4 allele (rs429358 C, rs7412 C) (130Arg, 176Arg). Phenotype: Increased incidence of chronic plaque psoriasis and guttate psoriasis, but no difference in response of psoriasis to the drug acitretin. Study size: 306 cases, 137 controls. Study population/ethnicity: Patients with chronic plaque psoriasis (n = 212), guttate psoriasis (n = 94). Significance metric(s): p =0.008 Type of association: CO; GN
GeneAPOE, APOC1
Featue
EvidencePubMed ID:16433808
Drugsacitretin
DiseasesPsoriasis
Curation LevelCurated
PharmGKBPA162360000
NameAPOE:Cys112Arg, 2060T>C, ApoE epsilon 4
AnnotationThe ApoE epsilon4 variant (2060C) is associated with hyperlipidemia (elevated triglyceride levels) in HIV-infected individuals treated with ritonavir.
GeneAPOE, APOC1
Featue
EvidencePubMed ID:15809899; PubMed ID:16417409; PubMed ID:17700364
Drugsritonavir
DiseasesHIV, HIV Infections, Hyperlipidemias
Curation LevelCurated
PharmGKBPA165110264
NameAPOE: epsilon3, defined as rs429358 T 130Cys + rs7412 C 176Arg
AnnotationRisk or phenotype-associated allele: APOE: epsilon3/epsilon3 (defined as rs429358 T/T 130Cys/Cys + rs7412 C/C 176Arg/Arg). Phenotype: Neurodegenerative disease characterized by asymmetric parietal atrophy, visuospatial dysfunction, incomplete Balint's syndrome, environmental agnosia, left-sided motor symptoms including dystonic postures and myoclonus in the left hand, without significant dementia (as in posterior cortical atrophy) was observed in a woman with early-onset neurodegenerative disease progressing 10 years from onset at age 52 to death. Study size: 1. Study population/ethnicity: Right-handed female/Japanese. Significance metric(s): non significant case report. Type of association: CO; GN
GeneAPOE, APOC1
Featue
EvidencePubMed ID:9804125
Drugs
DiseasesNeurodegenerative Diseases, Posterior Cortical Atrophy
Curation LevelCurated
PharmGKBPA165109612
NameAPOE: Cys112Arg (g.7903T>C, c.388T>C, p.Cys130Arg in dbSNP build 130)
AnnotationRisk or phenotype-associated allele: The ApoE E4 allele is a combination of rs429358 C (130Arg) and rs7412 C (176Arg). Phenotype: The Apo E4 allele is associated with 80 percent increased risk of dying (mortality risk ratio = 1.8) compared with other patients upon evaluation at 5.5 years following survival of myocardial infarction. ApoE E4 carriers who had high Lp(a) levels had a risk ratio of 3.7 of coronary death. Simvastatin treatment reduced the mortality risk to 0.33 in Apoe E4 carriers and to 0.66 in other patients (p = 0.23 for treatment by genotype interaction). Study size: 966 survivors of myocardial infarction enrolled in the Scandinavian Simvastatin Survival Study. Study population/ethnicity: Danish and Finnish. Significance metric(s): mortality risk ratio = 1.8. Type of association: CO; PD; GN
GeneAPOE, APOC1
Featue
EvidencePubMed ID:10736278
Drugssimvastatin
DiseasesInfarction, Myocardial Infarction
Curation LevelCurated
PharmGKBPA165109614
NameAPOE: Cys112Arg (g.7903T>C, c.388T>C, p.Cys130Arg in dbSNP build 130)
AnnotationRisk or phenotype-associated allele: The APOE E4 allele is a combination of rs429358 C (130Arg) and rs7412 C (176Arg). Phenotype: The APOE E4 allele (130Arg, 176Arg) was studied relative to the E3 (130Cys, 176Arg) and E2 (130Cys, 176Cys) alleles. Relative to the homozygous E3/E3 diplotype, Caucasians showed increased risk of Alzheimer Disease (AD): OR = 2.6 for E4/E2, OR = 3.2 for E4/E3, OR = 14.9 for E4/E4. The E2 allele was protective against risk of AD: OR = 0.6 for E2/E2, OR = 0.6 for E3/E2. Japanese showed greater increased risk of AD than Caucasians: OR=5.6 for E3/E4, OR = 33.1 for E4/E4. Study size: 5930 patients who met criteria for probable or definite AD, and 8607 controls without dementia. Study population/ethnicity: A clinic-/autopsy-based case-control study of patients between 40 and 90 years old recruited from clinical, community, and brain bank sources./Caucasian, African American, Hispanic, Japanese. Significance metric(s): OR. Type of association: CO; GN
GeneAPOE, APOC1
Featue
EvidencePubMed ID:9343467
Drugs
DiseasesAlzheimer Disease
Curation LevelCurated
PharmGKBPA165109616
NameAPOE: Cys112Arg (g.7903T>C, c.388T>C, p.Cys130Arg in dbSNP build 130)
AnnotationRisk or phenotype-associated allele: The E3 and E4 alleles of APOE, defined by the combined genotype at rs429358T>C (Cys130Arg) and rs7412C>T (Arg176Cys). Phenotype: The APOE E3 allele (130Cys, 176Arg) and E4 (130Arg, 176Arg) alleles were protective. Carriers of the E3 allele had significantly higher average macular thickness in both eyes (p = 0.012), and significantly better visual acuity (p = 0.041) than non-E3 carriers. E4 carriers showed reduced incidence of cataract than non-APOE4 carriers (p = 0.039). Study size: 32 patients who underwent cataract surgery in both eyes, and 56 controls. Study population/ethnicity: Patients from London, England aged 50-75 years old. Significance metric(s): p-value. Type of association: CO; GN
GeneAPOE, APOC1
Featue
EvidencePubMed ID:18498549
Drugs
DiseasesCataract, Macular Degeneration
Curation LevelCurated

[PMID 21263195] An APOE Haplotype Associated with Decreased ?4 Expression Increases the Risk of Late Onset Alzheimer's Disease

GWAS snp
PMID [PMID 21123754]
Trait
Title Genome-wide association study of CSF biomarkers A{beta}1-42, t-tau, and p-tau181p in the ADNI cohort.
Risk Allele
P-val 0.000001
Odds Ratio None None


[PMID 22174202] Apolipoprotein E Gene Polymorphisms Are Strong Predictors of Inflammation and Dyslipidemia in Rheumatoid Arthritis

Personal tools
Namespaces
Variants
Actions
Navigation
Toolbox